Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eo...
| 出版年: | Biologics: Targets & Therapy |
|---|---|
| 第一著者: | |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Dove Medical Press
2017-06-01
|
| 主題: | |
| オンライン･アクセス: | https://www.dovepress.com/patient-profiles-and-clinical-utility-of-mepolizumab-in-severe-eosinop-peer-reviewed-article-BTT |